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Received June 28, 2013; accepted July 25, 2013AbstractBackground: Lipopolysaccharide binding protein (LBP) is an acute-phase protein produced by the liver. It has been shown that LBP plays an
important role in the inflammatory response to sepsis. LBP has also been shown to protect animals from endotoxin challenge by facilitating the
removal of endotoxin from the blood circulation. Cirrhotic patients are susceptible to bacterial infection. It is unknown whether pre-existing liver
dysfunction impacts the LBP levels and thus the prognosis in severe sepsis.
Methods: We evaluated the serum LBP, inflammatory cytokines, and the relationship between LBP concentrations, functional liver reserve and
outcomes in 58 critically ill cirrhotic patients with severe sepsis.
Results: The serum LBP levels were significantly higher in 28-day survivors, while the interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a)
levels were significantly higher in non-survivors. We analyzed the receiver operating characteristic (ROC) curve to determine the cut-off point
for LBP to predict 28-day mortality. The cumulative rates at 28 days were 58.3% versus 16.7% for the high LBP group (>46 ng/mL) and low
LBP group (<46 ng/mL) ( p < 0.001). The high-LBP group had significantly lower INR, Child-Pugh, Model for End-stage Liver Disease
(MELD) scores and TNF-a level. Meanwhile, the LBP levels were inversely correlated with INR, and Child-Pugh, MELD and sequential organ
failure assessment (SOFA) scores.
Conclusion: The concentration of LBP is associated inversely with disease severity scores and outcomes in critically ill cirrhotic patients with
severe sepsis.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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http://dx.doi.org/10.1016/j.jcma.2013.10.006survival.1e4 Lipopolysaccharide (LPS), a component of the cell
membrane of Gram-negative bacteria, plays a central role in the
pathophysiology of sepsis.5,6 In response to endotoxin challenge,
cirrhotic patients show an augmented capacity to produce pro-
inflammatory cytokines, 710 which may be linked to multiple
organ dysfunction in severe sepsis. Despite advances in intensive
care, the prognosis for severe sepsis in liver cirrhosis is still
poor.11,12 Recognition of bacterial components by the innate
immune system is an important event for triggering the inflam-
matory response, which is necessary to eliminate the invading
microorganisms. Lipopolysaccharide-binding protein (LBP) is ahinese Medical Association. All rights reserved.
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cytes and granulocytes to LPS by facilitating binding of LPS to
the CD14 cell membrane molecule and Toll-like receptor 4,
activating the innate immune system by releasing inflammatory
cytokines, such as tumor necrosis factor-a (TNF-a) and
interleukin-6 (IL-6).5,6 In several clinical settings, serum LBP
seems to better reflect the long-term exposure to bacteria and
their endotoxins than endotoxin itself.13e15 In fact, in cirrhotic
patients without bacterial infection, increased levels of LBP can
identify a subset of ascitic cirrhotic patients with increased levels
of cytokines and a more pronounced vasodilatation.15 However,
LBP mediates LPS transfer to high-density lipoprotein (HDL)
particles, leading to neutralization of LPS.16,17 Taken together,
LBP may have dual effects in terms of modulation of the innate
immune response.18 Indeed, it has been shown that LBP plays a
concentration-dependent dual role in the pathogenesis of sepsis.
Low levels of LBP enhance the LPS-induced activation of
mononuclear cells (MNC), whereas the acute-phase rise in LBP
concentrations inhibits LPS-induced cellular stimulation.18,19
After the pathophysiological role of LBP was unraveled, the
diagnostic and prognostic values of LBP in patients with sys-
temic inflammatory response syndrome (SIRS) and sepsis have
been evaluated. Although the levels of LBP have been consis-
tently high in patients with SIRS and sepsis,13,20 the diagnostic
and prognostic values of LBP in different clinical settings have
been conflicting.13,20,21 The reason for these discrepancies is
unclear and probably due to heterogeneity of patient groups.
Like many other acute phase proteins, LBP is mainly
synthesized in the liver.22 Accordingly, upregulation of LBP
may be compromised in case of impaired synthetic capacity of
the liver, making the interpretation difficult. Severe sepsis can
precipitate acute or chronic liver failure in cirrhotic patients
and induce a wide array of metabolic and immunological
abnormalities.23,24 Although the clinical relevance of LBP has
been shown in stable cirrhotic patients without bacterial
infection,15 the prognostic significance of LBP has never been
evaluated in cirrhotic patients with severe sepsis. Considering
the impaired biosynthesis of LBP in cirrhotic liver and the
bipolar role that LBP plays in innate immunity, the prognostic
values of LBP in cirrhotic patients with severe sepsis may be
quite different from those of other clinical entities. Therefore,
we conducted this prospective observational study to investi-
gate whether the levels of LBP are associated with poor out-
comes in patients with liver cirrhosis and severe sepsis. Other
potential indicators of inflammation such as c-reactive protein
(CRP), TNF-a, and IL-6 were also measured.
2. Methods2.1. Patient information, data collection, and definitionsThis study was conducted with the approval of the institu-
tional review board of Chang Gung Memorial Hospital,
Taiwan. Formal consent was obtained from the next of kin. The
study enrolled 58 consecutive cirrhotic patients with severe
sepsis requiring intensive monitoring and/or treatment. Severe
sepsis was defined by the criteria of the American College ofChest Physicians/Society of Critical Care Medicine,25 namely
sepsis associated with organ dysfunction, hypoperfusion ab-
normality, or sepsis-induced hypotension. Liver cirrhosis was
defined histologically or based on clinical, image, and labora-
tory findings. All patients were treated with a standard treat-
ment protocol for management of severe sepsis and septic
shock.26 Management included early targeted resuscitation,
broad empiric antibiotic coverage, infection source control, and
effective shock evaluation and treatment. The empiric antibi-
otic therapy was as previously described.12,27 The empiric
antibiotic regimen was modified on the basis of microbiolog-
ical data. The major outcome analyzed was 28-day mortality.
The severity of liver disease on the day of blood sampling
was graded by the Child-Pugh and Model for End-stage Liver
Disease (MELD) scores.28,29 Meanwhile, multiple organ
dysfunction also was assessed by sequential organ failure
assessment (SOFA) scores.30e32 For these scoring systems and
physiological evaluations, the most abnormal value for each
organ system on the day of blood sampling was recorded.
Bacteremia was defined as the presence of viable bacteria in
the blood,25 as evidenced by a positive blood culture. Sponta-
neous bacteremia was defined as bacteremia without identified
infection focus. Culture-negative sepsis was defined as the
presence of systemic inflammatory response syndrome (SIRS)25
and negative cultures after exclusion of the possibility of non-
infection inflammatory conditions as the causes of SIRS.2.2. Laboratory investigationsBlood cultures and appropriate cultures from the infection
focus were obtained. Hematological and biochemical data were
also collected systemically within 24 hours of admission to ICU.
Fasting blood samples were obtained in the morning. The
blood samples were allowed to clot and were spun immedi-
ately in a refrigerated centrifuge. The serum was obtained and
frozen at 80C. LBP was measured by an enzyme-linked
immunosorbent assay (Cell Sciences, Inc, Canton, MA). The
concentrations of TNF-a and IL-6 were measured by an
enzyme-linked immunosorbent assay (R & D Systems, Min-
neapolis, MN). C-reactive protein was measured by a latex-
enhanced immunoturbidimetric method (Daiichi Pure Chem-
ical, Ibaraki, Japan).2.3. Statistical analysisDescriptive statistics are expressed as mean  SD. All vari-
ables were tested for normal distribution using the Kolmogorov-
Smirnov test. Student’s t test was used to compare the means of
continuous variables and the normal distribution data. Other-
wise, the Mann-Whitney U test was used. Categorical data were
tested using the Chi-square (c2) test. The correlation between
LBP levels and disease severity scores was analyzed with linear
regression using the Pearson method. Discrimination was tested
using the area under a receiver operating characteristic (ROC)
curve33 to assess the ability of LBP to predict 28-day mortality.
ROC analysis was also performed to calculate the cut-off
values, sensitivity, specificity, overall correctness, and positive
Table 1
Patients’ demographic data and clinical characteristics grouped according to 28-day mortality.
All patients (n ¼ 58) 28 days survival (n ¼ 22) 28 days non-survival (n ¼ 36) p
Age (y) 55.3  13.1 56.7  16.8 54.4  10.4 NS (0.532)
Sex (M/F) 46/12 18/6 30/6 NS (0.333)
BUN (mg/dL) 56.0  46.7 36.1  24.2 68.1  52.9 0.010
Serum creatinine (mg/dL) 3.43  2.96 2.00  1.94 4.32  3.14 0.003
Na (mEq/L) 140  7.8 140  6.1 139  8.7 NS (0.652)
K (mEq/L) 3.6  1.0 3.5  0.6 3.8  1.2 NS (0.281)
Bilirubin (mg/dL) 15.5  12.3 7.9  9.8 20.1  11.4 <0.001
PT prolongation (s) 15.2  14.3 7.4  5.4 20.0  15.9 0.001
Albumin (g/dL) 2.67  0.50 2.64  0.52 2.69  0.50 NS (0.698)
MAP (mmHg) 68.3  13.8 75  8 64  15 0.002
IL-6 (pg/mL) 220 (72e660) 71.5 (35e179) 327 (196e717) <0.001
TNF-a (pg/mL) 23.0 (11.2e40.1) 9 (4.9e19.3) 33.5 (24e76.5) <0.001
CRP (mg/L) 35.1 (19.7e73.6) 39 (15.8e69) 32 (20.8e83) NS (0.960)
LBP (ng/mL) 42.2  21.5 55.5  15.8 34.0  19.0 <0.001
SOFA score 12.6  5.4 8.2  3.2 15.3  4.6 <0.001
MELD score 31.9  13.7 21.2  8.8 38.6  11.8 <0.001
Child-Pugh score 11.4  2.4 9.7  2.2 12.4  1.8 <0.001
BUN ¼ blood urea nitrogen; CRP ¼ C reactive protein; F ¼ female; LBP ¼ lipopolysaccharide-binding protein; M ¼ male; MAP ¼ mean arterial pressure;
MELD ¼ Model for End-stage Liver Disease; NS ¼ not significant; OSF ¼ organ system failure; SOFA ¼ sequential organ failure assessment.
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(sensitivity þ specificity e 1)34 was also used to determine the
best cut-off point of LBP to predict 28-day mortality. All sta-
tistical tests were two-tailed, and the significance level was set at
p ¼ 0.05 or less. Data were analyzed using SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL, USA).
3. Results3.1. Patients’ characteristicsFifty-eight critically ill cirrhotic patients were enrolled in
this investigation. The cause of liver cirrhosis was hepatitis B
virus (HBV) in 26 patients, alcohol in 17, hepatitis C virus
(HCV) in nine, HBV plus alcohol in two, HBV plus HCV in
three, and an unknown cause in one. Overall, the ICU and 28-Table 2
Patients’ demographic data and clinical characteristics grouped according to LBP.
All patients (n ¼ 58) High LBP(>46 n
Age (y) 55.3  13.1 56.6  14.2
Sex (M/F) 46/12 17/5
ICU mortality rate 34 (58.6%) 7 (31.8%)
28-d mortality rate 36 (62.1%) 6 (27.3%)
BUN (mg/dL) 56.0  46.7 49.3  42.0
Serum creatinine (mg/dL) 3.43  2.96 2.56  2.16
Na (mEq/L) 140  7.8 143  6
K (mEq/L) 3.6  1.0 3.5  0.7
Bilirubin (mg/dL) 15.5  12.3 12.0  12.6
PT prolongation (s) 15.2  14.3 9.6  6.8
Albumin (g/dL) 2.67  0.50 2.66  0.39
MAP (mmHg) 68.3  13.8 71  13
IL-6 (pg/mL) 220 (72e660) 129 (35e655.8)
TNF-a (pg/mL) 23.0 (11.2e40.1) 11.5 (5.4e28.9)
CRP (mg/L) 35.1 (19.7e73.6) 50.3 (29.7e98)
SOFA score 12.6  5.4 10.23  5.11
MELD score 31.9  13.7 26.3  12.0
Child-Pugh score 11.4  2.4 10.6  2.5
BUN ¼ blood urea nitrogen; F ¼ female; LBP ¼ lipopolysaccharide-binding prote
Liver Disease; NS ¼ not significant; OSF ¼ organ system failure; SOFA ¼ sequeday mortality rates for the entire group were 58.6% and
62.1%, respectively. Table 1 lists the patients’ demographic
data and clinical characteristics. Compared to survivors, the
non-survivors had higher disease severity and poorer liver
reserve as evidenced by higher SOFA, MELD, and Child-Pugh
scores. Microbiological information was available for all pa-
tients. Fifty-two patients had at least one positive microbio-
logical culture. Positive cultures were obtained from the blood
in 27 (46.5%) patients, from urine in 16 (27.5%), from sputum
in 18 (31.0%), from ascites in 16 (27.5%) patients, and from a
CVP catheter tip in two (3.4%).3.2. Concentrations of LBP and cytokinesThe levels of LBP were significantly higher in those who
survived (Table 1), while the levels of TNF-a and IL-6 wereg/mL) (n ¼ 22) Low LBP (46 ng/mL) (n ¼ 36) p
54.5  12.5 NS (0.559)
29/7 NS (0.765)
27 (75.0%) 0.001
30 (83.3%) <0.001
60.1  49.5 NS (0.379)
3.96  3.28 NS (0.057)
138  8 0.005
3.7  1.1 NS (0.531)
17.6  11.7 NS (0.095)
18.6  16.5 0.018
2.68  0.57 NS (0.861)
67  14 NS (0.305)
231 (114e660) NS (0.167)
29.5 (17.8e50.5) 0.011
26.6 (17.2e68.1) NS (0.091)
14.00  5.08 0.008
35.4  13.6 0.011
11.9  2.2 NS (0.058)
in; M ¼ male; MAP ¼ mean arterial pressure; MELD ¼ Model for End-stage
ntial organ failure assessment.
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with higher levels of TNF-a (Table 2). The levels of LBP were
inversely correlated with Child-Pugh, MELD, and SOFA
scores (Fig. 1).
The discriminating power of LBP to predict 28-day mor-
tality was tested using the area under a receiver operating
characteristic (ROC) curve. The area under ROC curve forFig. 1. Linear regression using the Pearson method to assess the corLBP was 0.809 [95% CI: 0.691e0.927] (Fig. 2). By analyzing
the ROC curve, the cut-off point for LBP to best predict 28-
day mortality was obtained (46 ng/mL; sensitivity: 72.7%;
specificity: 83.3%).
The clinical characteristics and outcomes in patient sub-
groups stratified by LBP level are listed in Table 2. The ICU
and 28-day mortality rates for the patients who had a lowerrelation between the LBP levels and the disease severity scores.
Fig. 2. Receiver operating characteristic (ROC) curve to test the discriminating
power of LBP to predict 28-day mortality. The area under ROC curve for LBP
is 0.809 (95% CI: 0.691e0.927).
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LBP. Follow-up to 28 days or the time of death was complete
for the entire groups. The cumulative rates of survival at 28
days were 16.7% and 72.7% for the low-LBP group and high-
LBP group, respectively ( p < 0.001) (Fig. 3).
To clarify further whether the association between low
levels of LBP and mortality was confounded by liver
dysfunction and the severity of multiple organ dysfunction, we
tried to compare the concentrations of LBP between the 28-
day survivors and non-survivors with comparable Child-
Pugh, MELD, and SOFA scores. We used the median values
as cut-off values to stratify the patients into high and low
groups of different prognostic scores. The differences in the
levels of LBP between survivors and non-survivors remained,
while the differences in Child-Pugh scores between survivors
and non-survivors had been eliminated (Table 3), suggestingFig. 3. Cumulative survival in patients with high (n ¼ 22) and low (n ¼ 36)
LBP after admission to intensive care unit. Day 0 indicates the 1st day of
admission to intensive care unit.that LBP level was associated with mortality independent of
liver dysfunction. However, the differences in the levels of
LBP between survivors and non-survivors did not consistently
remain when we stratified patients using MELD and SOFA
scores (Supplementary Tables 1 and 2).
4. Discussion
This study is the first to evaluate the relationship between
levels of serum LBP and outcomes in critically ill cirrhotic
patients with severe sepsis. This investigation showed that low
levels of LBP at admission to ICU are associated with
impaired liver reserve, multiple organ dysfunction and
increased mortality in this clinical setting.
Bacterial translocation and episodic endotoxemia are
common phenomena in cirrhotic patients.35,36 Although LBP
has served as a surrogate marker of bacterial translocation in
liver cirrhosis,2,15 its clinical value in the setting of sepsis
remains inconclusive. Data about the association between LBP
concentrations at admission to the ICU and outcomes have
been conflicting. In this study, we found that 28-day mortality
rates were significantly higher in patients with lower levels of
LBP at admission to ICU. This finding is in agreement with
previous studies,13,37 but in contrast to others, in which high
levels of LBP were either associated with adverse out-
comes38,39 or not related to outcomes.21,40 Despite the con-
flicting data about the prognostic significance of LBP in the
literature, the dynamics of LBP levels during sepsis were
consistent. The higher levels were observed at the initial tests
and decreased thereafter, with the lowest at the last
tests.21,37,40 The reasons for this dynamic trend are not clear.
Although Prucha et al reported that liver failure was not likely
to be responsible for this phenomenon in a study of small
sample size,21 their conclusion should not readily be extrap-
olated to cirrhotic patients, in whom acute or chronic liver
failure may occur in the setting of severe sepsis and may
impact the biosynthesis of LBP.
Investigators have reported dual biological activity of LBP,
namely both pro- and anti-inflammatory properties.18 In
contrast to the upregulation of the LPS-induced cytokine
release by LBP, an LPS-neutralizing effect has also been
observed at high concentrations of LBP. LBP could suppress
endotoxin-triggered cytokine secretion and prevent liver fail-
ure, leading to a significantly increased survival rate in
endotoxin-challenged mice as well as in a murine model of
bacteremia.19 However, Zweigner et al investigated whether
high levels of acute-phase concentrations of LBP in patients
with severe sepsis could modulate the LPS-induced TNF-a
secretion from monocytes.41 They found that serum containing
high concentrations of LBP from septic patients could reduce
TNF-a overproduction, an effect that was reversed by LBP
depletion. In agreement of this contention, our results showed
that TNF-a levels were significantly lower in the high LBP
group.
Interestingly, in patients with sequential episodes of sepsis,
LBP response seems to be of lesser magnitude following each
consecutive episode of sepsis.37 This phenomenon may
Table 3
Lipopolysaccharide-binding protein and outcome data in patient subgroups stratified by Child-Pugh scores.
Low Child-Pugh groupa High Child-Pugh groupb
28-d survivors
(n ¼ 18)
28-d non-survivors
(n ¼ 10)
p (Mann-Whitney) 28-d survivors
(n ¼ 4)
28-d non-survivors
(n ¼ 26)
p (Mann-Whitney)
LBP (ng/mL) 53.0  19.4 38.1  24.1 0.031 67.5  15.3 32.4  16.9 0.005
IL-6 (pg/mL) 138  216 423  412 0.029 243  321 609  715 NS (0.143)
TNF-a (pg/mL) 10.8  9.7 28.7  18.7 0.003 38.8  48.9 77.2  83.0 NS (0.065)
Child-Pugh score 9.00  1.73 10.1  1.10 NS (0.102) 12.75  1.50 13.31  1.05 NS (0.268)
LBP ¼ lipopolysaccharide-binding protein; NS ¼ not significant.
a Child-Pugh score  11.
b Child-Pugh score > 11; the value used as cut-off was the median value.
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patients with severe sepsis, in whom low levels of LBP may
reflect both impaired hepatic synthesis and accumulating
adverse effects of sequential sepsis episodes in susceptible
individuals.
The mechanisms behind how LBP prevents endotoxin-
induced toxicity remain unclear. It has been shown that
LBP in vivo is associated with HDL.17 Moreover, LBP fa-
cilitates transfer of LPS into HDL, resulting in a detoxifica-
tion process.17,42,43 In this regard, our group has shown that
serum levels of HDL are inversely correlated with liver
reserve, disease severity, and levels of inflammatory cyto-
kines in cirrhotic patients with severe sepsis.12 Taken
together, impaired synthesis of HDL and LBP from diseased
livers may make cirrhotic patients even more susceptible to
the toxicity of bacterial products. High levels of endotoxin
during sepsis may further overwhelm the already impaired
neutralization ability provided by low levels of HDL and LBP
and subsequently become even more unopposed, thus
perpetuating the overproduction of inflammatory cytokines. A
vicious cycle ensues, with further failure of multiple organ
functions.
In contrast to subgroup analysis stratified by the Child-
Pugh score, the differences in the levels of LBP between
survivors and non-survivors did not consistently remain in the
sub-group analysis stratified by MELD and SOFA scores
(Supplementary Tables 1 and 2). Because both MELD and
SOFA scores evaluate extra-hepatic organ function in addition
to hepatic function, our findings suggested the significant
confounding effects of extra-hepatic dysfunction on the asso-
ciation between LBP and outcomes. In this regard, LBP may
impact survival through its pathophysiological link with
multiple organ failure. Further studies are needed to clarify
this issue.
There are limitations in our study. First, we only measured
LBP levels at admission to ICU. As previously discussed, the
concentrations of LBP levels may vary significantly over the
course of a given septic episode.21,37,40 Secondly, our study
suffers from absence of a non-cirrhotic control group. There-
fore, the impact of pre-existing chronic liver failure on LBP
levels cannot be elucidated. Finally, the case number is small.
We need a bigger cohort to allow better sub-group analyses to
evaluate the confounding effects of disease scores on the as-
sociation between LBP levels and mortality.In conclusion, low serum levels of LBP are associated with
increased concentrations of TNF-a and adverse outcomes of
cirrhotic patients with severe sepsis. These findings may shed
light on the pathophysiology in cirrhosis with severe sepsis.
Whether the levels of LBP can enable clinicians to identify
those patients who are at risk for deterioration and in need of
timely intervention is unknown. It is also unknown whether
recombinant LBP can serve as an adjuvant therapeutic strategy
in cirrhosis with endotoxemia.44 For potential clinical appli-
cation of LBP, further investigations on the best timing of the
testing and dosing regimen in order to achieve a protective
effect of LBP are needed.
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